Breakdown | |||||
TTM | Jun 2024 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
31.43M | 35.32M | 28.92M | 8.60M | 2.87M | 2.06M | Gross Profit |
20.15M | 23.61M | 19.95M | 5.83M | 2.24M | 1.21M | EBIT |
-46.04M | -59.04M | -3.00 | -4.74M | -1.77M | -1.80M | EBITDA |
-41.21M | -43.16M | 24.12K | -3.99M | -1.56M | -1.76M | Net Income Common Stockholders |
-51.68M | -57.48M | -9.09M | -5.18M | -1.76M | -1.94M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
2.17M | 1.19M | 5.82M | 6.87M | 6.22M | 1.28M | Total Assets |
55.14M | 56.86M | 116.73M | 22.77M | 9.37M | 3.86M | Total Debt |
44.54M | 45.85M | 48.97M | 1.95M | 391.25K | 287.79K | Net Debt |
42.37M | 44.66M | 43.15M | -4.92M | -5.83M | -990.11K | Total Liabilities |
69.80M | 74.70M | 72.72M | 6.46M | 1.11M | 736.34K | Stockholders Equity |
-40.82M | -43.56M | 19.29M | 14.68M | 8.26M | 3.12M |
Cash Flow | Free Cash Flow | ||||
1.04M | 3.04M | -15.49M | -4.73M | -1.85M | -1.72M | Operating Cash Flow |
1.48M | 4.50M | -10.00M | -4.22M | -1.68M | -1.59M | Investing Cash Flow |
-122.21K | -1.48M | -43.45M | -4.40M | -382.62K | -126.60K | Financing Cash Flow |
-1.01M | -4.78M | 52.41M | 9.27M | 7.00M | 72.75K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | C$247.59M | 5.25 | 29.02% | 0.45% | -19.66% | 15.33% | |
65 Neutral | $8.92B | 15.03 | 4.68% | 6.11% | 3.59% | -2.49% | |
49 Neutral | $5.42M | ― | -231.01% | ― | 121.88% | 77.93% | |
47 Neutral | C$25.54M | ― | -32.62% | ― | -39.06% | -9.07% | |
41 Neutral | $5.21M | ― | 260.66% | ― | ― | ― | |
40 Underperform | C$8.31M | ― | ― | -15.73% | -45.92% |
Deveron Corp. has entered into a forbearance agreement with Toronto Dominion Bank concerning a $26 million loan, allowing the bank to refrain from exercising its rights due to certain defaults until September 30, 2025, or upon specific termination events. This agreement supports Deveron’s strategic review process to explore alternatives for meeting short-term liquidity needs, potentially impacting its operations and market positioning.
Spark’s Take on TSE:FARM Stock
According to Spark, TipRanks’ AI Analyst, TSE:FARM is a Underperform.
Deveron UAS faces significant challenges, including high leverage, negative profitability, and recent revenue declines, impacting its financial performance. Technical indicators suggest limited momentum, while valuation metrics reflect the company’s struggles. Corporate events underscore operational and regulatory hurdles, leading to a cautious outlook on the stock.
To see Spark’s full report on TSE:FARM stock, click here.
Deveron Corp. announced the resignation of Mr. Albert Contardi from its board of directors, effective immediately. The company expressed gratitude for his contributions and wished him success in future endeavors. This change in leadership comes as Deveron continues to focus on its core mission of enhancing agricultural productivity through technology-driven insights, potentially impacting its strategic direction and stakeholder relations.
Spark’s Take on TSE:FARM Stock
According to Spark, TipRanks’ AI Analyst, TSE:FARM is a Underperform.
Deveron UAS’s overall stock score is low due to significant financial challenges, including high debt levels and ongoing losses. Although revenue growth is a positive aspect, it is overshadowed by the company’s precarious financial health and lack of profitability. The stable technical indicators and poor valuation metrics further contribute to the overall low score.
To see Spark’s full report on TSE:FARM stock, click here.
Deveron Corp. reported a decrease in revenue and adjusted EBITDA for the second quarter of fiscal 2025, attributed to softer sales in its Canadian fertility and specialty tissue products, macroeconomic challenges in the North American agricultural sector, and the company’s exit from its unprofitable carbon business. Operating expenses were reduced by 22% due to cost optimization and headcount reductions, reflecting the company’s efforts to streamline operations amidst challenging market conditions.
Deveron Corp. has released its audited financial results for the year ending June 2024 and the quarter ending September 2024. The company experienced a slight decline in revenue by 3.5% for the year, but saw a significant improvement in Adjusted EBITDA, which increased by 347%. However, the company recorded an impairment charge of $43,132,423, attributed mainly to goodwill from the acquisition of lab testing businesses. Additionally, Deveron’s financial performance was impacted by seasonal tissue volumes and the exit from the US carbon service business. The company is working with the Ontario Securities Commission to address a review of its continuous disclosure after being subjected to a cease trade order for more than 120 days.